BIOMATERIALS - Peeref

Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.

Journal Title

BIOMATERIALS

ISSN / eISSN

0142-9612 / 1878-5905

Aims and Scope

Biomaterials is an international journal covering the science and clinical application of biomaterials. A biomaterial is now defined as a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct, by control of interactions with components of living systems, the course of any therapeutic or diagnostic procedure. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review and opinion papers dealing with the most important issues facing the use of biomaterials in clinical practice. The scope of the journal covers the wide range of physical, biological and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used. These sciences include polymer synthesis and characterization, drug and gene vector design, the biology of the host response, immunology and toxicology and self assembly at the nanoscale. Clinical applications include the therapies of medical technology and regenerative medicine in all clinical disciplines, and diagnostic systems that reply on innovative contrast and sensing agents. The journal is relevant to areas such as cancer diagnosis and therapy, implantable devices, drug delivery systems, gene vectors, bionanotechnology and tissue engineering.

Subject Area

ENGINEERING, BIOMEDICAL

MATERIALS SCIENCE, BIOMATERIALS

CiteScore

23.40

View Trend

CiteScore Ranking

Category	Quartile	Rank
Biochemistry, Genetics and Molecular Biology - Biophysics	Q1	#2/143
Biochemistry, Genetics and Molecular Biology - Ceramics and Composites	Q1	#2/123
Biochemistry, Genetics and Molecular Biology - Mechanics of Materials	Q1	#6/391
Biochemistry, Genetics and Molecular Biology - Biomaterials	Q1	#5/125
Biochemistry, Genetics and Molecular Biology - Bioengineering	Q1	#8/153

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
ENGINEERING, BIOMEDICAL - SCIE	Q1
MATERIALS SCIENCE, BIOMATERIALS - SCIE	Q1

H-index

337

Country/Area of Publication

NETHERLANDS

Publisher

Elsevier BV

Publication Frequency

Biweekly

Year Publication Started

1980

Annual Article Volume

572

Open Access

Contact

ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB

Popular journals in the same field
Recent articles

Harnessing human adipose-derived stromal cell chondrogenesis In vitro for enhanced endochondral ossification: (2023) Mansoor Chaaban, Adrien Moya, Andres García-García, Robert Paillaud, Romain Schaller, Thibaut Klein, Laura Power, Katarzyna Buczak, Alexander Schmidt,...

Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy: (2023) Mingqi Chen, Yucui Shen, Yinying Pu, Bangguo Zhou, Jinhong Bing, Min Ge, Yaxuan Zhu, Shuang Gao, Wencheng Wu, Min Zhou, Jianlin Shi

Glucose-primed PEEK orthopedic implants for antibacterial therapy and safeguarding diabetic osseointegration: (2023) Miaomiao He, Hao Wang, Qiuyang Han, Xiuyuan Shi, Shuai He, Jiyu Sun, Zhuoli Zhu, Xueqi Gan, Yi Deng

Cationic mesoporous silica nanoparticles alleviate osteoarthritis by targeting multiple inflammatory mediators: (2023) Tongfei Shi, Jingtong Zhao, Kongrong Long, Mohan Gao, Fangman Chen, Xuenian Chen, Yue Zhang, Baoding Huang, Dan Shao, Chao Yang, Liang Wang, Ming Zhan...

Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation: (2023) Yejin Sung, Seung Taek Hong, Mihue Jang, Eun Sun Kim, Chansoo Kim, Youngmee Jung, Inchan Youn, Ick Chan Kwon, Seung-Woo Cho, Ju Hee Ryu

Pillar arene Se nanozyme therapeutic systems with dual drive power effectively penetrated mucus layer combined therapy acute lung injury: (2023) Xu Chen, Yonglan Yang, Qiongmei Mai, Gang Ye, Yanan Liu, Jie Liu

Biomaterial-mediated targeted therapeutics of myocardial ischemia-reperfusion injury: (2023) Qiang Luo, Wei Sun, Zhibo Li, Jinfeng Sun, Yu Xiao, Jichang Zhang, Cuilin Zhu, Bin Liu, Jianxun Ding

High rapamycin-loaded hollow mesoporous Prussian blue nanozyme targets lesion area of spinal cord injury to recover locomotor function: (2023) Kui Shen, Xiaowei Li, Guanning Huang, Zhongwen Yuan, Bin Xie, Tianfeng Chen, Lizhen He

Blood brain barrier-targeted delivery of double selenium nanospheres ameliorates neural ferroptosis in Alzheimer's disease: (2023) Jingyuan Wang, Zekun Wang, Yuqing Li, Yajun Hou, Chenyang Yin, Endong Yang, Ziyu Liao, Cundong Fan, Lisandra L. Martin, Dongdong Sun

Synchronized activating therapeutic nano-agent: Enhancement and tracing for hypoxia-induced chemotherapy: (2023) Han Zhang, Chao Shi, Fuping Han, Lihan Cai, He Ma, Saran Long, Wen Sun, Jianjun Du, Jiangli Fan, Xiaoqiang Chen, Xiaojun Peng

Verified Reviews

Note: Verified reviews are sourced from across review platforms and social media globally.

The second manuscript, BM, explored a new field that the laboratory had not previously touched upon, and a lot of effort was put into investigating the mechanisms. It was submitted on July 16, 2020, and rejected on September 18, 2020. There were two reviewers, one of whom accepted it directly, while the other requested major revisions. However, the editor rejected it outright. This left me puzzled. Following the suggestions of the second reviewer, we conducted additional experiments to address the questions raised. On December 8, 2020, we resubmitted the revised manuscript. However, it seemed to have disappeared into thin air, as the status remained at "with editor." During this time, I sent an email to the editor once to inquire about the manuscript's status. The reply stated that the manuscript had been found and was being handled by another editor. Finally, on March 2021, when I casually checked the status, it showed that the manuscript had been accepted directly. The submission process was tumultuous and frustrating, but fortunately, it ultimately yielded a positive outcome.

2021-03-16

7.7 submission, 8.2 first review comments received, editor requested revisions by 9.30, revised manuscript uploaded and responded to comments on 9.20, accepted on 9.29.

The two reviewers raised a total of eighty-nine questions, all of which were explicitly recommended for acceptance during the first review. The experiments that needed to be supplemented were relatively simple except for the animal experiments, which were more complex. Our research project has a large amount of data, and various mechanistic experiments have been verified from multiple angles, with detailed work.

Originally, we thought that it might not be submitted for review, or it would take at least six months to be accepted. However, due to the increasing influence in recent years, it has become more and more difficult to submit. The result was surprisingly fast. The impact factor for this year has increased to 15.3, and the quality of the articles published in Biomaterials is also very good and highly recognized. I wish Biomaterials continued success!

2022-09-30

View All Reviews

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.